Papillary Renal Cell Carcinoma – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Papillary Renal Cell Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions.
Papillary renal cell carcinoma (PRCC), a form of kidney cancer, originates in the tubes responsible for filtering waste from the blood. There are two subtypes: Type 1, more common and slow-growing, and type 2, aggressive and fast-growing. Symptoms may include blood in urine, pain, weight loss, fatigue, fever, or a palpable lump. Diagnosis involves imaging scans like CT, MRI, and ultrasound, and confirmation through biopsy. Treatment is personalized, often involving surgery to remove tumors, though options vary with disease progression. Radiation therapy targets tumor areas, and chemotherapy is considered when surgery is impractical or in cases of metastasis.
The Papillary Renal Cell Carcinoma drugs in development market research report provide comprehensive information on the therapeutics under development for Papillary Renal Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Papillary Renal Cell Carcinoma and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Papillary Renal Cell Carcinoma | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 20 molecules, with 20 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Papillary Renal Cell Carcinoma therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Papillary Renal Cell Carcinoma pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Papillary Renal Cell Carcinoma treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AstraZeneca PlcBristol-Myers Squibb Co
Byondis BV
DeuterOncology NV
Exelixis Inc
F. Hoffmann-La Roche Ltd
Hibercell Inc
Instil Bio Inc
Johnson & Johnson
Mersana Therapeutics Inc
Novartis AG
Oncorena AB
Pfizer Inc
ProfoundBio Suzhou Co Ltd
RemeGen Co Ltd
Salubris Biotherapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Papillary Renal Cell Carcinoma reports